Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases cases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: A method of installing and removing a rotation mechanism within a plurality of pill dispensing assemblies, the method including installing the rotation mechanism in a first pill dispensing assembly of the plurality of pill dispensing assemblies, removing the rotation mechanism from the first pill dispensing assembly, and installing the rotation mechanism in a second pill dispensing assembly of the plurality of pill dispensing assemblies.

Abstract: A split seal ring having end faces that self-align in both the axial and radial directions is prepared by forming an opposing first pair of angled grooves extending from an inner edge partway across the seal ring inner diameter, and a second pair of angled grooves extending from the inner edge partway across the seal ring rear surface. In embodiments, corresponding grooves meet to form V-shapes. Additional grooves can extend from the outer edge partway across the inner diameter. Corresponding grooves extending from the outer and inner edges on the inner diameter can terminate at locations that are offset radially and/or angularly. By applying an outward force, the seal ring is split at the groove locations into split ring sections having mating end faces. The resulting end face geometry is sufficiently complex to cause both radial and axial realignment as the seal ring halves are mated together.

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: A dispensing assembly, including a case including at least one aperture, a drive gear operatively arranged to engage the case, a tablet disc rotatably arranged in the case and including a plurality of compartments, and an electronics assembly, including a motor engaged with the drive gear, and a housing operatively arranged to engage the tablet disc, wherein the motor is arranged to rotate the electronics assembly and the tablet disc with respect to the case to align the plurality of compartments with the at least one aperture.

Abstract: A control server in communication with a content delivery network (CDN) node and a client device may include a client controller configured to receive a manifest from the CDN defining a plurality of content segments of a master content available at the CDN, and receive client information from the client device. The control server may generate, based on the client information, one player manifest for each of a plurality of client device media players of the client device to control access of each client device media player to appropriate ones of the plurality of content segments based on the client information.

Abstract: A tablet and capsule dispensing assembly, comprising a case including an inner circumferential surface having a first plurality of teeth a tablet disc having a plurality of tablets disposed circumferentially thereon, the tablet disc arranged to rotate within the case, and a lock arranged to engage with the first plurality of teeth to prevent rotation of the tablet disc in a first rotational direction during a first predetermined time interval.

Abstract: A human insulin-like growth factor (IGF) binding protein stock solution and method of making the same include a non-recombinant human IGF binding protein-3 (nr-IGFBP-3) in an aqueous buffered medium. The concentration of the nr-IGFBP-3 in the stock solution ranges from about 16 micrograms per milliliter (?g/ml) to about 40 ?g/ml. A kit includes a set of calibrators for nr-IGFBP-3. The set of calibrators includes the nr-IGFBP-3 in different concentrations that are within a range of from about 0.5 ?g/ml to about 16 ?g/ml, which is configured to span a suspected range of IGFBP-3 analyte levels in an immunoassay of patient samples.

Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Abstract: A bottom garment for providing comfort to the wearer. The bottom garment may include a front panel and a back panel, both the front panel and the back panel formed of a high weft-stretch fabric. The bottom garment may also include a garment lining formed of a higher weft-stretch fabric, low weight fabric attached on the inside of the panels inside of the garment, above a crotch point of the bottom garment. The stretch in the weft direction of the garment lining is greater than a stretch in the weft direction of the front panel and the back panel. The stretch in the warp direction of the garment lining is less than the stretch in the weft direction of the garment lining. The bottom garment may further include an elastic support band for maintaining the position of the garment when the garment is worn.

Abstract: A dispensing assembly which includes a case having a superior component and inferior component, the superior component and inferior component operatively arranged to form a first cavity therebetween. A tablet disc is arranged within the first cavity having a plurality of tablets disposed about a circumference of the tablet disc, where the tablet disc is arranged to rotate about a central axis and within the case. The assembly further includes a lock to prevent rotation of the tablet disc in a first rotational direction during a first predetermined time interval. The lock includes a first component and a second component. The first component includes a display and a first circuit connected to the display. The second component includes an actuator, a catch, a plurality of teeth on an outer circumferential surface of the second component, and a ratchet operatively arranged to engage with the plurality of teeth and the case.

Abstract: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Abstract: Provided are compositions and methods for use in prophylaxis of puerperal metritis and improving reproductive function of ruminants. The methods and compositions are for subcutaneous administration and are provided as veterinary compositions and as articles of manufacture. The veterinary composition can contain whole cells selected from whole cells of Escherichia coli (E. coli), Trueperella pyogenes (T. pyogenes), Fusobacterium necrophorum (F. necrophorum) and combinations thereof; and/or proteins selected from F. necrophorum leukotoxin (LKT), E. coli type 1 fimbrial adhesin (FimH), T. pyogenes pyolysin (PLO), and all combinations of the whole cells and the proteins.

Abstract: This disclosure generally relates to a system, which includes a processor to receive video of a cymatic effect. The video of the cymatic effect may be converted into a virtual reality effect which includes a virtual reality representation of the cymatic effect. The virtual reality effect may then be output by the processor to a virtual reality device for display to a user.

Abstract: An improved leadframe assembly for use in a quad flat no lead (QFN) package is described along with a method of fabricating both the leadframe assembly and the QFN package. The leadframe assembly comprises an etch-stop layer formed on a topside of a substrate and a routing layer (or trace) formed on a topside of the etch-stop layer. The etch-stop layer prevents etching of an underside of the routing trace and the leadframe assembly may also comprise a top plating layer formed on a topside of the routing layer and which prevents etching of the topside of the routing trace.

Abstract: Provided are compositions and methods for use in prophylaxis of puerperal metritis and improving reproductive function of ruminants. The methods and compositions are for subcutaneous administration and are provided as veterinary compositions and as articles of manufacture. The veterinary composition can contain whole cells selected from whole cells of Escherichia coli (E. coli), Trueperella pyogenes (T. pyogenes), Fusobacterium necrophorum (F. necrophorum) and combinations thereof; and/or proteins selected from F. necrophorum leukotoxin (LKT), E. coli type 1 fimbrial adhesin (FimH), T. pyogenes pyolysin (PLO), and all combinations of the whole cells and the proteins.

Abstract: The introduction of electronics into a drug delivery device may introduce certain technical challenges, such as durability, electro-mechanical integration, and drug delivery performance. The present disclosure provides solutions for inclusion of an electronics module with an inhaler. For example, heat stakes may be used to secure a printed circuit board (PCB) to an electronics module's housing. Also for example, a slider may be used to transfer vertical movement of an inhaler's yoke to an electronics module's switch. Also for example, certain seals may be used when interfacing the electronics module to other portions of the device's housing to achieve a desired performance.

Abstract: Methods for obtaining natural colorants from plant material (e.g., tobacco material) and for using such natural colorants to dye various substrates are provided. Natural colorants are obtained using particular enzymes and particular conditions (e.g., time, temperature, and pH profiles). Such colorants can be used to dye substrates, for example, using conventional dyeing techniques or using unique in situ methods.